- Home
- MVST vs IPHA Comparison
MVST vs IPHA Comparison
Compare MVST & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MVST
- IPHA
- Stock Information
- Founded
- MVST 2006
- IPHA 1999
- Country
- MVST United States
- IPHA France
- Employees
- MVST N/A
- IPHA N/A
- Industry
- MVST Industrial Machinery/Components
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- MVST Miscellaneous
- IPHA Health Care
- Exchange
- MVST Nasdaq
- IPHA Nasdaq
- Market Cap
- MVST 182.8M
- IPHA 148.3M
- IPO Year
- MVST N/A
- IPHA 2019
- Fundamental
- Price
- MVST $1.99
- IPHA $1.82
- Analyst Decision
- MVST Buy
- IPHA Strong Buy
- Analyst Count
- MVST 3
- IPHA 1
- Target Price
- MVST $3.33
- IPHA $11.50
- AVG Volume (30 Days)
- MVST 20.2M
- IPHA 785.4K
- Earning Date
- MVST 11-12-2024
- IPHA 09-12-2024
- Dividend Yield
- MVST N/A
- IPHA N/A
- EPS Growth
- MVST N/A
- IPHA N/A
- EPS
- MVST N/A
- IPHA N/A
- Revenue
- MVST $370,989,000.00
- IPHA $36,202,722.00
- Revenue This Year
- MVST $19.19
- IPHA N/A
- Revenue Next Year
- MVST $29.35
- IPHA $102.87
- P/E Ratio
- MVST N/A
- IPHA N/A
- Revenue Growth
- MVST 39.03
- IPHA N/A
- 52 Week Low
- MVST $0.15
- IPHA $1.29
- 52 Week High
- MVST $2.87
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- MVST 54.10
- IPHA 47.15
- Support Level
- MVST $1.82
- IPHA $1.64
- Resistance Level
- MVST $2.87
- IPHA $1.95
- Average True Range (ATR)
- MVST 0.46
- IPHA 0.12
- MACD
- MVST -0.05
- IPHA -0.04
- Stochastic Oscillator
- MVST 40.14
- IPHA 35.57
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry to battery packs.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.